Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.
Schardt JS, Oubaid JM, Williams SC, Howard JL, Aloimonos CM, Bookstaver ML, Lamichhane TN, Sokic S, Liyasova MS, O'Neill M, Andresson T, Hussain A, Lipkowitz S, Jay SM.
Schardt JS, et al. Among authors: liyasova ms.
Mol Pharm. 2017 Apr 3;14(4):1047-1056. doi: 10.1021/acs.molpharmaceut.6b00919. Epub 2017 Mar 8.
Mol Pharm. 2017.
PMID: 28248115
Free PMC article.